Literature DB >> 19306327

The increased incidence of the RET p.Gly691Ser variant in French-Canadian vesicoureteric reflux patients is not replicated by a larger study in Ireland.

John M Darlow1, Niamh H N Molloy, Andrew J Green, Prem Puri, David E Barton.   

Abstract

The p.Gly691Ser variant of the RET protein, resulting from the 'A' allele of the SNP rs1799939 in exon 11 of the RET gene, was recently found to be present in a high proportion of primary vesicoureteric reflux (pVUR) patients in Quebec. We have determined the genotype of this SNP in 221 unrelated index cases of pVUR from the Irish population, in 190 full siblings of 160 of the index cases, and in 592 healthy controls. We found no significant difference in genotype or allele frequencies in patients and controls, and no tendency of affected siblings to share the same genotype. We also found no difference in the presence of additional phenotypic features such as duplex kidneys, between patients with and without the 'A' allele, and no difference in grade of reflux. We find no evidence of any influence of RET SNP rs1799939 on pVUR phenotype. Copyright 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19306327     DOI: 10.1002/humu.21009

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  8 in total

1.  Traditional and targeted exome sequencing reveals common, rare and novel functional deleterious variants in RET-signaling complex in a cohort of living US patients with urinary tract malformations.

Authors:  Rajshekhar Chatterjee; Enrique Ramos; Mary Hoffman; Jessica VanWinkle; Daniel R Martin; Thomas K Davis; Masato Hoshi; Stanley P Hmiel; Anne Beck; Keith Hruska; Doug Coplen; Helen Liapis; Robi Mitra; Todd Druley; Paul Austin; Sanjay Jain
Journal:  Hum Genet       Date:  2012-06-23       Impact factor: 4.132

Review 2.  Genetics of innate immunity and UTI susceptibility.

Authors:  Bryndís Ragnarsdóttir; Nataliya Lutay; Jenny Grönberg-Hernandez; Bela Köves; Catharina Svanborg
Journal:  Nat Rev Urol       Date:  2011-07-12       Impact factor: 14.432

Review 3.  Genetics of vesicoureteral reflux.

Authors:  Prem Puri; Jan-Hendrik Gosemann; John Darlow; David E Barton
Journal:  Nat Rev Urol       Date:  2011-08-23       Impact factor: 14.432

4.  Primary, nonsyndromic vesicoureteric reflux and nephropathy in sibling pairs: a United Kingdom cohort for a DNA bank.

Authors:  Heather J Lambert; Aisling Stewart; Ambrose M Gullett; Heather J Cordell; Sue Malcolm; Sally A Feather; Judith A Goodship; Timothy H J Goodship; Adrian S Woolf
Journal:  Clin J Am Soc Nephrol       Date:  2011-03-24       Impact factor: 8.237

Review 5.  Congenital Disorders of the Human Urinary Tract: Recent Insights From Genetic and Molecular Studies.

Authors:  Adrian S Woolf; Filipa M Lopes; Parisa Ranjzad; Neil A Roberts
Journal:  Front Pediatr       Date:  2019-04-11       Impact factor: 3.418

6.  A Case of 123I-Metaiodobenzylguanidine Scintigraphy-Negative Pheochromocytoma with a Tumor-Developing Mutation in the RET Gene.

Authors:  Haremaru Kubo; Yuya Tsurutani; Takashi Sunouchi; Yoshitomo Hoshino; Rei Hirose; Sho Katsuragawa; Noriko Kimura; Jun Saito; Tetsuo Nishikawa
Journal:  J Clin Med       Date:  2022-08-08       Impact factor: 4.964

7.  Whole-genome linkage and association scan in primary, nonsyndromic vesicoureteric reflux.

Authors:  Heather J Cordell; Rebecca Darlay; Pimphen Charoen; Aisling Stewart; Ambrose M Gullett; Heather J Lambert; Sue Malcolm; Sally A Feather; Timothy H J Goodship; Adrian S Woolf; Rajko B Kenda; Judith A Goodship
Journal:  J Am Soc Nephrol       Date:  2009-12-03       Impact factor: 10.121

8.  A new genome scan for primary nonsyndromic vesicoureteric reflux emphasizes high genetic heterogeneity and shows linkage and association with various genes already implicated in urinary tract development.

Authors:  J M Darlow; M G Dobson; R Darlay; C M Molony; M Hunziker; A J Green; H J Cordell; P Puri; D E Barton
Journal:  Mol Genet Genomic Med       Date:  2013-07-07       Impact factor: 2.183

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.